Telomeres and telomerase: Biological and clinical importance in dogs

Veterinary Journal

Volumn 175, Issue 2, 2008, Pages 155-163

  Nasir, Lubna ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Canine; Telomerase; Telomere

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIBR 1532; BRACO 19; CYTOSINE DEAMINASE; DOCETAXEL; FLUCYTOSINE; ONCOLYTIC VIRUS; PEPTIDE NUCLEIC ACID; PRODRUG; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; TUMOR ANTIGEN; ZIDOVUDINE;

APOPTOSIS; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL AGING; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; DNA DAMAGE; DOG DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REACTIVATION; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NONVIRAL GENE THERAPY; POSTTRANSCRIPTIONAL GENE SILENCING; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SENESCENCE; SURVIVAL TIME; TELOMERE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL DIVISION; DOG DISEASES; DOGS; NEOPLASMS; TELOMERASE; TELOMERE;

ANIMALIA; CANIS FAMILIARIS;

EID: 44249095856     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2007.01.024     Document Type: Review

References (110)

1. Adaikalakoteswari A., Balasubramanyam M., and Mohan V. Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Diabetic Medicine 229 (2005) 1151-1156
2. Amarnath S.M., Dyer C.E., Ramesh A., Iwuagwu O., Drew P.J., and Greenman J. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. International Journal of Oncology 25 (2004) 211-217
3. Argyle D., Ellsmore V., Gault E.A., Munro A.F., and Nasir L. Equine telomeres and telomerase in cellular immortalisation and ageing. Mechanisms of Ageing Development 124 (2003) 759-764
4. Argyle D.J., McKevitt T., Gault E., and Nasir L. Evaluation of telomerase targeted therapies in canine cancer cell lines. Veterinary and Comparative Oncology 2 (2004) 214-221
5. Argyle D.J., and Nasir L. Telomerase: a potential diagnostic and therapeutic tool in canine oncology. Veterinary Pathology 40 (2003) 1-7
6. Avilion A.A., Piatyszek M.A., Gupta J., Shay J.W., Bacchetti S., and Greider C.W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Research 56 (1996) 645-650
7. Ben-Porath I., and Weinberg R.A. When cells get stressed: an integrative view of cellular senescence. Journal of Clinical Investagation 113 (2004) 8-13
8. Bilsland A.E., Anderson C.J., Fletcher-Monaghan A.J., McGregor F., Evans T.R., Ganly I., Knox R.J., Plumb J.A., and Keith W.N. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22 (2003) 370-380
9. Blackburn E.H. Structure and function of telomeres. Nature 350 (1991) 569-573
10. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nature Reviews Genetics 6 (2005) 611-622
11. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., and Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 279 (1998) 349-352
12. Boon T.P., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. Journal of Experimental Medicine 183 (1996) 725729
13. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dorken B., Jenuwein T., and Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
14. Broccoli D., Young J.W., and de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proceedings of the National Academy of Science (USA) 92 (1995) 9082-9086
15. Burger A.M. Highlights in experimental therapeutics. Cancer Letters 245 (2007) 11-21
16. Burger A.M., Dai F., Schultes C.M., Reszka A.P., Moore M.J., Double J.A., and Neidle S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Research 65 (2005) 1489-1496
17. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. Journal of the American Geriatrics Society 45 (1997) 482-488
18. Campisi J. The biology of replicative senescence. European Journal of Cancer 33 (1997) 703-709
19. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends in Cell Biology 11 (2001) S27-S31
20. Canales B.K., Li Y., Thompson M.G., Gleason J.M., Chen Z., Malaeb B., Corey D.R., Herbert B.S., Shay J.W., and Koeneman K.S. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Urologic Oncology 24 (2006) 141-151
21. Carioto L.M., Kruth S.A., Betts D.H., and King W.A. Telomerase activity in clinically normal dogs and dogs with malignant lymphoma. American Journal of Veterinary Research 62 (2001) 1442-1446
22. Colitz C.M.H., Barden C.A., Lu P., and Chandler H.L. Expression and characterization of the catalytic subunit of telomerase in normal and cataractous canine lens epithelial cells. Molecular Vision 12 (2006) 1067-1076
23. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., and Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
24. Cookson J.C., Dai F., Smith V., Heald R.A., Laughton C.A., Stevens M.F., and Burger A.M. Pharmacodynamic of the G-quadruplex-stabilizing telomerase inhibitor 3,11-0rdifluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]-acridinium methosulfate (RHPS4)in vitro: activity in human tumor cells correlates with telomere length and can be enhanced. Molecular Pharmacology 68 (2005) 1551-1558
25. Corey D.R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 21 (2002) 631-637
26. Counter C.M., Gupta J., Harley C.B., Leber B., and Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85 (1995) 2315-2320
27. Counter C.M., Hahn W.C., Wei W., Caddle S.D., Beijersbergen R.L., Lansdorp P.M., Sedivy J.M., and Weinberg R.A. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proceedings of the National Academy of Science USA 95 (1998) 14723-14728
28. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes and Development 19 (2005) 2100-2110
29. de Souza Nascimento P., Alves G., and Fiedler W. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncology Reports 162 (2006) 423-428
30. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., and Pereira-Smith O. A Biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences (USA) 9 (1995) 9363-9367
31. Dobson J.M., Samuel S., Milstein H., Rogers K., and Wood J.L. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. Journal of Small Animal Practice 43 (2002) 240-246
32. Effros R.B. Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy. Cancer Immunology and Immunotherapy 53 (2004) 925-933
33. Epel E.S., Blackburn E.H., Lin J., Dhabhar F.S., Adler N.E., Morrow J.D., and Cawthon R.M. Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Science (USA) 101 (2004) 17312-17315
34. Falchetti M.L., Fiorenzo P., Mongiardi M.P., Petrucci G., Montano N., Maira G., Pierconti F., Larocca L.M., Levi A., and Pallini R. Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurology Research 28 (2006) 532-537
35. Folini M., Colella G., Villa R., Lualdi S., Daidone M.G., and Zaffaroni N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. Journal of Investigative Dermatology 114 (2000) 259-267
36. Folini M., and Zaffaroni N. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies. Current Pharmaceutical Design 11 (2005) 1105-1117
37. Fujiwara T., Kagawa S., Kishimoto H., Endo Y., Hioki M., Ikeda Y., Sakai R., Urata Y., Tanaka N., and Fujiwara T. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. International Journal of Cancer 119 (2006) 432-440
38. Funakoshi Y., Nakayama H., Uetsuka K., Nishimura R., Sasaki N., and Doi K. Cellular proliferative and telomerase activity in canine mammary gland tumors. Veterinary Pathology 37 (2000) 177-183
39. Gisselsson D., Jonson T., Petersen A., Strombeck B., Dal Cin P., Hoglund M., Mitelman F., Mertens F., and Mandahl N. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proceedings of the National Academy of Science (USA) 23 (2001) 12683-12688
40. Gowan S.M., Heald R., Stevens M.F., and Kelland L.R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Molecular Pharmacology 60 (2001) 981-988
41. Greider C.W. Telomerase activity, cell proliferation, and cancer. Proceeding of the National Academy of Science (USA) 95 (1998) 90-92
42. Greenberg R.A., Allsopp R.C., Chin L., Morin G.B., and DePinho R.A. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 16 (1998) 1723-1730
43. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., and de Lange T. Mammalian telomeres end in a large duplex loop. Cell 97 (1999) 503-514
44. Gu J., Andreeff M., Roth J.A., and Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy 9 (2002) 30-37
45. Hakin-Smith V., Jellinek D.A., Levy D., Carroll T., Teo M., Timperley W.R., McKay M.J., Reddel R.R., and Royds J.A. Alternative lengthening of telomeres and survival in patients with gliobastoma multiforme. Lancet 361 (2003) 836-838
46. Hamilton S.E., Simmons C.G., Kathiriya I.S., and Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chemistry and Biology 6 (1999) 343-351
47. Hansen K., and Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. European Journal of Cancer 40 (2004) 858-880
48. Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345 (1990) 458-460
49. Henson J.D., Hannay J.A., McCarthy S.W., Royds J.A., Yeager T.R., Robinson R.A., Wharton S.B., Jellinek D.A., Arbuckle S.M., Yoo J., Robinson B.G., Learoyd D.L., Stalley P.D., Bonar S.F., Yu D., Pollock R.E., and Reddel R.R. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clinical Cancer Research 11 (2005) 217-225
50. Hipple A.K., Colitz C.M.H., Mauldin G.M., and Cho D.Y. Telomerase activity and related properties of normal canine lymph node and canine lymphoma. Veterinary and Comparative Oncology 1 (2003) 140-151
51. Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M.A., Shay J.W., Ishioka S., and Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. Journal of Immunology 155 (1995) 3711-3715
52. Karlseder J., Smogorzewska A., and de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 295 (2002) 2446-2449
53. Keith W.N., Bilsland A., Hardie M., and Evans T.R. Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology 1 (2004) 88-96
54. Khurts S., Masutomi K., Delgermaa L., Arai K., Oishi N., Mizuno H., Hayashi N., Hahn W.C., and Murakami S. Nucleolin interacts with telomerase. Journal of Biological Chemistry 279 (2004) 51508-51515
55. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
56. Kim M.Y., Vankayalapati H., Shin-Ya K., Wierzba K., and Hurley L.H. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. Journal of the American Chemical Society 124 (2002) 2098-2099
57. Koga S., Hirohata S., Kondo Y., Komata T., Takakura M., Inoue M., Kyo S., and Kondo S. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Research 21 (2001) 1937-1943
58. Komata T., Kondo Y., Kanzawa T., Ito H., Hirohata S., Koga S., Sumiyoshi H., Takakura M., Inoue M., Barna B.P., Germano I.M., Kyo S., and Kondo S. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Human Gene Therapy 13 (2002) 1015-1025
59. Kondo S., Kondo Y., Li G., Silverman R.H., and Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16 (1998) 3323-3330
60. Leri A., Barlucchi L., Limana F., Deptala A., Darzynkiewicz Z., Hintze T.H., Kajstura J., Nadal-Ginard B., and Anversa P. Telomerase expression and activity are coupled with myocyte proliferation and preservation of telomeric length in the failing heart. Proceedings of the National Academy of Science (USA) 98 (2001) 8626-8631
61. Leonetti C., Amodei S., D'Angelo C., Rizzo A., Benassi B., Antonelli A., Elli R., Stevens M.F., D'Incalci M., Zupi G., and Biroccio A. Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]-acridinium methosulfate) is associated with telomere capping alteration. Molecular Pharmacology 66 (2004) 1138-1146
62. Li S., Crothers J., Haqq C.M., and Blackburn E.H. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. Journal of Biological Chemistry 280 (2005) 23709-23717
63. Lin T., Huang X., Gu J., Zhang L., Roth J.A., Xiong M., Curley S.A., Yu Y., Hunt K.K., and Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21 (2002) 8020-8028
64. Liu J., Zou W.G., Lang M.F., Luo J., Sun L.Y., Wang X.N., Qian Q.J., and Liu X.Y. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. International Journal of Oncology 21 (2002) 661-666
65. Long S., Argyle D.J., Campbell S., Gault E., and Nasir L. The canine telomerase catalytic subunit (dogTERT): characterisation of the gene promoter and identification of proximal core sequences necessary for specific transcriptional activity in canine telomerase positive cell lines. Gene 358 (2005) 111-120
66. Long S., Argyle D.J., Nixon C., Nicholson I., Botteron C., Olby N., Platt S., Smith K., Ruttema G.R., Grinwis G.C.M., and Nasir L. An immunohistochemical study of telomerase reverse transcriptase (TERT) and MIB-1 expression in canine brain tumours. Neurobiology and Applied Neuropathology 32 (2006) 662-673
67. Makarov V.L., Hirose Y., and Langmore J.P. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88 (1977) 657-666
68. Martin-Rivera L., Herrera E., Albar J.P., and Blasco M.A. Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proceedings of the National Academy of Science (USA) 95 (1998) 10471-10476
69. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., Weinberg R.A., Stewart S.A., and Hahn W.C. Telomerase maintains telomere structure in normal human cells. Cell 114 (2003) 241-253
70. McKevitt T.P., Nasir L., Devlin P., and Argyle D.J. Telomere Lengths in Dogs Decrease with Increasing Donor Age. Journal of Nutrition 132 (2002) 1604-1606
71. McKevitt T.P., Nasir L., Wallis C.V., and Argyle D.J. A cohort study of telomere and telomerase biology in cats. American Journal of Veterinary Research 64 (2003) 1496-1499
72. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., and Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (1997) 785-795
73. Minamino T., and Komuro I. Role of telomere in endothelial dysfunction in atherosclerosis. Current Opinion in Lipidology 13 (2002) 537-543
74. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., and Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105 (2002) 1541-1544
75. Mishima K., Handa J.T., Aotaki-Keen A., Lutty G.A., Morse L.S., and Hjelmeland L.M. Senescence-associated beta-galactosidase histochemistry for the primate eye. Investigative Ophthalmology and Visual Science 40 (1999) 1590-1593
76. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., Kuzushima K., Takiguchi M., and Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006) 1284-1294
77. Nair S.K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J.S., Vieweg J., and Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Medicine 6 (2000) 1011-1017
78. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., Harley C.B., and Cech T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science 277 (1997) 955-959
79. Nasir L., Devlin P., Mckevitt T., Rutteman G., and Argyle D.J. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 3 (2001) 351-359
80. Pallini R., Sorrentino A., Pierconti F., Maggiano N., Faggi R., Montano N., Maira G., Larocca L.M., Levi A., and Falchetti M.L. Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. International Journal of Cancer 118 (2006) 2158-2167
81. Panarese S., Brunetti B., and Sarli G. Evaluation of telomerase in canine mammary tissues by immunohistochemical analysis and a polymerase chain reaction-based enzyme-linked immunosorbent assay. Journal of Veterinary Diagnostic Investigation 18 (2006) 362-368
82. Parkhurst M.R., Riley J.P., Igarashi T., Li Y., Robbins P.F., and Rosenberg S.A. Immunization of patients with the hTERT:540-548 peptide induces peptide reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clinical Cancer Research 10 (2004) 4688-4698
83. Plumb J.A., Bilsland A., Kakani R., Zhao J., Glasspool R.M., Knox R.J., Evans T.R., and Keith W.N. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20 (2001) 7797-7803
84. Renwick M.G., Argyle D.J., Long S., Nixon C., Gault E.A., and Nasir L. Telomerase Activity and cTERT expression in canine lymphoma: correlation with Ki67 immunoreactivity. Veterinary Comparative Oncology 4 (2006) 141-150
85. Robson T., and Hirst D.G. Transcriptional Targeting in Cancer Gene Therapy. Journal of Biomedicine and Biotechnology 2003 (2003) 110-137
86. Rodier F., Kim S.H., Nijjar T., Yaswen P., and Campisi J. Cancer and aging: the importance of telomeres in genome maintenance. International Journal of Biochemistry and Cell Biology 37 (2005) 977-990
87. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10 (1999) 281-287
88. Seimiya H., Muramatsu Y., Ohishi T., and Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7 (2005) 25-37
89. Sen G.L., and Blau H.M. A brief history of RNAi: the silence of the genes. The Faseb Journal 20 (2006) 1293-1299
90. Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., and Munshi N.C. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Molecular Cancer Therapeutics 2 (2003) 825-833
91. Shammas M.A., Simmons C.G., Corey D.R., and Shmookler Reis R.J. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene 18 (1999) 6191-6200
92. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. European Journal of Cancer 33 (1997) 787-791
93. Simon N.M., Smoller J.W., McNamara K.L., Maser R.S., Zalta A.K., Pollack M.H., Nierenberg A.A., Fava M., and Wong K.K. Shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biological Psychiatry 60 (2006) 432-435
94. Smogorzewska A., Karlseder J., Holtgreve-Grez H., Jauch A., and de Lange T. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Current Biology 12 (2002) 1635-1644
95. Su Z., Dannull J., Yang B.K., Dahm P., Coleman D., Yancey D., Sichi S., Niedzwiecki D., Boczkowski D., Gilboa E., and Vieweg J. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. Journal of Immunology 174 (2005) 3798-3807
96. Titu L.V., Loveday R.L., Madden L.A., Cawkwell L., Monson J.R., and Greenman J. Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients. Oncology Reports 12 (2004) 871-876
97. Ulaner G.A., Huang H.Y., Otero J., Zhao Z., Ben-Porat L., Satagopan J.M., Gorlick R., Meyers P., Healey J.H., Huvos A.G., Hoffman A.R., and Ladanyi M. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Research 63 (2003) 1759-1763
98. Van Pel A., van der Bruggen P., Coulie P.G., Brichard V.G., Lethe B., van den Eynde B., Uyttenhobe C., Renauld J.C., and Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunological Reviews 145 (1995) 229-250
99. Vonderheide R.H., Domchek S.M., Schultze J.L., George D.J., Hoar K.M., Chen D.Y., Stephans K.F., Masutomi K., Loda M., Xia Z., Anderson K.S., Hahn W.C., and Nadler L.M. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clinical Cancer Research 10 (2004) 828-839
100. Watson J.D. The origin of concatemeric T7 DNA. Nature 239 (1972) 197-201
101. Wong S.C., Yu H., Moochhala S.M., and So J.B. .Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Anticancer Research 23 (2003) 465-469
102. Wright W.E., Tesmer V.M., Huffman K.E., Levene S.D., and Shay J.W. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes and Development 11 (1997) 2801-2809
103. Wu Y.L., Dudognon C., Nguyen E., Hillion J., Pendino F., Tarkanyi I., Aradi J., Lanotte M., Tong J.H., Chen G.Q., and Segal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. Journal of Cell Science 119 (2006) 2797-2806
104. Yazawa M., Okuda M., Setoguchi A., Iwabuchi S., Nishimura R., Sasaki N., Masuda K., Ohno K., and Tsujimoto H. Telomere lengths and telomerase activity in canine mammary gland tumors. American Journal of Veterinary Research 62 (2001) 1539-1543
105. Yazawa M., Okuda M., Setoguchi A., Nishamura R., Sasaki N., Hasegawa A., Toshihiro W., and Tsujimoto H. Measurement of Telomerase Activity in dog tumours. Journal of Veterinary Medical Science 61 (1999) 1125-1129
106. Yi X., Tesmer V.M., Savre-Train I., Shay J.W., and Wright W.E. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Molecular and Cellular Biology 19 (1999) 3989-3997
107. Yokoyama Y., Takahashi Y., Shinohara A., Lian Z., Wan X., Niwa K., and Tamaya T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Research 58 (1998) 5406-5410
108. You Y., Pu P., Huang Q., Xia Z., Wang C., Wang G., Yu C., Yu J.J., Reed E., and Li Q.Q. Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo. International Journal of Oncology 28 (2006) 1225-1232
109. Zaffaroni N., Villa R., Pennati M., and Folini M. Approaches for the inhibition of human telomerase based on the use of peptide nucleic acids and hammerhead ribozymes. Mini Reviews in Medicinal Chemistry 3 (2003) 51-60
110. Zhang P.H., Zou L., and Tu Z.G. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. Journal of Surgical Research 131 (2006) 143-149